预约演示
更新于：2026-07-18
SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey)
更新于：2026-07-18
概要
基本信息
药物类型 灭活疫苗、预防性疫苗 |
别名- |
作用方式 调节剂 |
作用机制 SARS-CoV-2 S protein调节剂(冠状病毒刺突糖蛋白调节剂) |
在研适应症- |
非在研适应症 |
在研机构- |
权益机构- |
最高研发阶段终止临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
1
项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的临床试验NCT04866069
Phase I Study Evaluating the Safety and Efficacy of the Protective Adjuvanted Inactivated Vaccine Developed Against SARS-CoV-2 in Healthy Participants, Administered as Two Injections Subcutaneously in Two Different Dosages.
100 项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的临床结果
登录后查看更多信息
100 项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的转化医学
登录后查看更多信息
100 项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的专利（医药）
登录后查看更多信息
799
项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的文献（医药）2026-09-01JOURNAL OF CLINICAL EPIDEMIOLOGY
Exclusion by design: enrollment criteria limit older adult participation in SARS-CoV-2 vaccine clinical trials
Article
作者: Johnson, Taylor N ; Chu, Helen Y ; Fohner, Alison E
BACKGROUND AND OBJECTIVES:
Older adults (≥65 years) face a disproportionate burden of COVID-19 mortality yet remain underrepresented in clinical trials despite this group accounting for 76% of COVID-19 deaths. Hundreds of SARS-CoV-2 vaccine clinical trials have been registered on ClinicalTrials.gov; however, the extent of older adult representation remains unclear. Our objective was to evaluate the representation of older adults in SARS-CoV-2 vaccine clinical trials registered on ClinicalTrials.gov and identify enrollment criteria that disproportionately limit older adult participation.
METHODS:
We conducted a retrospective, cross-sectional analysis of 207 global SARS-CoV-2 vaccine clinical trials registered on ClinicalTrials.gov between November 1, 2019, and September 30, 2025. For each trial, we extracted trial characteristics, participant age data, and enrollment criteria. Age distributions were modeled using reported summary statistics to estimate older adult representation. We compared these estimates to the US population age distribution and COVID-19 mortality. To identify contributing factors to underrepresentation, we systematically evaluated trial eligibility criteria for conditions that disproportionately affect older populations. We compared the age-specific prevalence of these conditions in the US population to their use as exclusion criteria across trials. Additionally, we examined whether trials that excluded common chronic conditions enrolled younger participant populations on average.
RESULTS:
We estimate that 63,223 out of 707,378 (9%) of participants across all trials were aged ≥65, despite older adults accounting for 18% of the US population and 76% of COVID-19-related deaths. Although only 35% of studies had explicit criteria for an upper age limit, we identified common study exclusion criteria, such as hypertension, diabetes, and cancer that are more prevalent among older adults and associated with lower mean participant ages when applied.
CONCLUSION:
These findings highlight persistent barriers to equitable inclusion of older adults in vaccine research and underscore the need to reconsider exclusion criteria that disproportionately affect this high-risk population to enhance the generalizability and applicability of clinical trial outcomes.
2026-07-01Journal of the American Medical Directors Association
Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination
Article
作者: Abul, Yasin ; Canaday, David H ; Nugent, Clare ; Gravenstein, Stefan ; Yavuz, Selma ; DeVone, Frank ; McConeghy, Kevin W ; Halladay, Christopher W ; Skov, Benjamin ; Rudolph, James L
OBJECTIVES:
Nursing home residents received updated monovalent SARS-CoV-2 vaccines to protect them from the most recently emerging SARS-CoV-2 variants. We evaluated nursing home residents for the extent and durability of protection from hospitalization or death after monovalent KP.2 vaccination.
DESIGN:
Retrospective cohort study using a target trial emulation design. We conducted a sequential, daily comparison of those who did and did not receive a KP.2 vaccination during the study period. Residents who received KP.2 were matched to unvaccinated residents based on index date and propensity scores incorporating demographics, vaccination status, and basic clinical characteristics.
SETTING AND PARTICIPANTS:
Long-stay residents living in Veterans Affairs nursing homes between September 18, 2024, and October 30, 2024.
METHODS:
The primary exposure was KP.2 vaccination vs no SARS-CoV-2 vaccine during the study period. The primary outcome was a test-confirmed SARS-CoV-2 infection. Secondary outcome was composite outcome of COVID-19-associated hospitalizations within 21 days or death within 30 days of confirmed infection.
RESULTS:
Among eligible residents, a matched cohort of 1711 paired person trials were created (average age 76, 95% male, 28% African American). Vaccine effectiveness against COVID-19 infection was 38% at week 12 (95% CI, 13%-56%) and 4% at week 18 (95% CI, -30 to 29%). Vaccine effectiveness against hospitalization or death was 77% at week 12 (95% CI, 60%-90%) and 53% at week 18 (95% CI, 21%-71%).
CONCLUSION AND IMPLICATIONS:
Vaccination with the KP.2 updated SARS-CoV-2 vaccine provided significant clinical protection against hospitalization or death among nursing home residents. This protection started to wane within a few months of vaccination, mirroring antibody decline reported in other studies. Our findings support consideration of twice-annual vaccination strategy to optimize protection in this vulnerable population.
2026-06-01CLINICAL IMMUNOLOGY
Autoimmunity following SARS-CoV-2 infection and vaccination: Systematic review and meta-analysis
Review
作者: Oudhini, Anouar ; Changuel, Maha ; Zanina, Youssef ; Elghali, Mourad ; Sakly, Nabil
AIM:
To systematically review and meta-analyze the available evidence on the association between SARS-CoV-2 infection, COVID-19 vaccination, and the development of new autoimmune conditions (AIC).
METHODS:
This study followed the PRISMA guidelines. MEDLINE, Scopus, Cochrane Library, and Google Scholar were searched until December 31, 2024, for studies reporting new-onset autoimmunity after SARS-CoV-2 infection or vaccination. Meta-analyses using random-effects models calculated pooled odds ratios using RStudio 4.3.
RESULTS:
Of the 2544 records identified, 39 studies were included in the systematic review, and 17 studies were included in the meta-analysis. A significant association was found between SARS-CoV-2 infection and new AIC (p = 0.0054) and particularly type 1 diabetes (p = 0.0229), blistering diseases (p = 0.0452), systemic sclerosis (p = 0.0153), and vitiligo (p = 0.0122). Regarding SARS-CoV-2 vaccine-induced autoimmunity, no association between COVID-19 vaccines and new AIC was observed.
CONCLUSION:
This study provides evidence that SARS-CoV-2 infection may strongly induce autoimmunity.
1
项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的新闻（医药）2026-06-29
100 项与 SARS-CoV-2 vaccine(The Scientific and Technological Research Council of Turkey) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床1期 | 土耳其 | 2021-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用